ERYTHROMYCIN LACTOBIONATE · NEXUS
Erythromycin lactobionate is an injectable antibiotic used when patients have severe infections or cannot take medications by mouth. It treats a variety of bacterial issues, including respiratory tract infections, skin infections, and erythrasma. Doctors often prescribe it to achieve high levels of the drug in the bloodstream quickly, or as an alternative for patients with penicillin sensitivities who have pelvic inflammatory disease.
How ERYTHROMYCIN LACTOBIONATE Works
This drug works by binding to the 50 S ribosomal subunits of susceptible bacteria, which stops the organism from producing necessary proteins. By inhibiting this protein synthesis, the medication prevents the bacteria from growing and spreading. This process specifically targets protein production without affecting the synthesis of nucleic acids.
Details
- Status
- Prescription
- First Approved
- 1964-06-25
- Routes
- INJECTION, Injection
- Dosage Forms
- INJECTABLE, Injectable
ERYTHROMYCIN LACTOBIONATE Approval History
What ERYTHROMYCIN LACTOBIONATE Treats
8 indicationsERYTHROMYCIN LACTOBIONATE is approved for 8 conditions since its original approval in 1989. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- Skin and Skin Structure Infection
- Diphtheria
- Erythrasma
- Pelvic Inflammatory Disease
- Legionnaires' Disease
- Rheumatic Fever
ERYTHROMYCIN LACTOBIONATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ERYTHROMYCIN LACTOBIONATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02755064 | 08-008620 UL1TR000135 | Ph 1 | completed | Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ERYTHROMYCIN LACTOBIONATE FDA Label Details
Indications & Usage
Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influen...
Looking for the branded version?
ERYTHROCIN
Full clinical data, patents, trials, and competitive landscape for erythromycin lactobionate.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.